Libsyn Directory

#68 A Leftist Primer on the Right-Wing Psychedelic Takeover

Release Date: 04/20/2026

The Psymposia Podcast

Psymposia board member Dr. Neşe Devenot’s presentation at the Ohio State University “Religion and Psychedelics” conference, recorded March 28, 2026. In this talk, Dr. Devenot presents their research on the reliance on unscientific telepathic attunement in many popular schools of psychedelic therapy.

#69 Why is Professor Dave Promoting Psychedelic Grifters?

The Psymposia Podcast

Professor Dave is a well-known science communicator and prolific debunker of pseudoscience. Despite building his platform on combatting misinformation, he continues joining conversations that promote false claims about the FDA’s rejection of MDMA-assisted therapy — one of which he republished on his own channel. In this episode, Psymposia responds to the latest of these conversations on the Danny Jones Podcast. We encourage Professor Dave to do his homework on the psychedelic industry before aligning himself with the very pseudoscience promoters he's built his career opposing.

#68 UPDATE: A Leftist Primer to the Right-Wing Psychedelic Takeover

The Psymposia Podcast

Three psychedelic companies received vouchers for expedited FDA review: Usona, Compass Pathways, and Otsuka—NOT Resilient Pharmaceuticals. This voucher announcement is yet another vindication of our reporting on major problems and pseudoscience within Lykos’/Resilient's trials. Update to episode #68.

#68 A Leftist Primer on the Right-Wing Psychedelic Takeover

The Psymposia Podcast

#67 Just Up the Dose?: Therapy Cults are Influencing Psychedelic Medicine Standards

The Psymposia Podcast

It has become a problematic standard practice in the psychedelic therapy industry to increase drug dosages after patients display red flag symptoms. Psymposia discusses a recent Wall Street Journal article about these practices as they manifest in the ketamine industry; the psychedelic industry’s historic normalization of these practices; and recent attempts to convince lawmakers to protect psychedelic providers from liability for standard forms of medical malpractice. Together, these developments highlight why allowing a therapy cult to influence the norms of psychedelic medicine puts the...

#66 Hamilton's Pharma Cope, Part 4: "The Face of Psychedelic Ethics"

The Psymposia Podcast

In this final episode, we explore the attempts made by Hamilton Morris to attack the work, integrity, and character of our team.

#65 Hamilton's Pharma Cope, Part 3: Paid Protestor Paranoia

The Psymposia Podcast

Psymposia discusses Hamilton Morris's misinformation about their funding, his relationship with Compass Pathways, his claims that the nonprofit Usona has planted protestors at conferences to make him look bad, and claims that Psymposia encouraged terrorism.

#64 Hamilton's Pharma Cope, Part 2: Psychedelic Cult Defenders

The Psymposia Podcast

Psymposia discusses their history with the Church of Psilomethoxin and addresses Hamilton Morris's misinformation about their funding and the alleged elder abuse of psychedelic funder George Sarlo by MAPS Board Chair Vicky Dulai.

#63 Hamilton's Pharma Cope, Part 1: "DEA Informants"

The Psymposia Podcast

Psymposia addresses Hamilton Morris's misinformation, including his speculation that they are DEA informants, their behavior at the FDA advisory committee for Lykos' Therapeutics' MDMA application, and more.

#62 Even More Psychedelic Figures in the Epstein Files

The Psymposia Podcast

Psymposia discusses more notable psychedelic figures who have turned up in the Epstein files — including Paul Krassner, Rupert and Merlin Sheldrake, Paul Daley, and more. 2:06: Kimbal Musk updates 4:48: Ken Jordan/Alchemist Kitchen updates 8:32: Rupert Sheldrake 20:00: Merlin Sheldrake 29:00 Cortes Island 34:20: Paul Krassner 41:05: Paul Daley Footnotes: Perversion of Justice: The Jeffrey Epstein story (Miami Herald): New batch of Epstein files unmasks a 1970s Scientology spy — and he talked to us! (The Underground Bunker): Epstein engineered intimate relationship for Tesla’s...

More Episodes

Psychedelics are the next front in Big Tech's dystopia. Psymposia developed this primer for leftists in response to Donald Trump‘s April 18 Executive Order, which accelerates review of psychedelic drugs deemed “Breakthrough Therapies” and makes Schedule 1 drugs more accessible under Right to Try laws. This announcement made a splash in psychedelic media, where praise for the Trump administration mixes with false claims about an “end to prohibition.” In this discussion, we provide important context about this Executive Order and the people who engineered this moment behind the scenes. We highlight concerns about how this initiative will be rolled out by the Trump administration, which has been accused of pay-to-play tactics at the FDA and stacking the Department of Health and Human Services with psychedelic industry evangelists. This move represents a crystallization of far-right interest in the psychedelic industry and step towards oligarch monopolization of psychedelic medicine by figures including Peter Thiel and Musk lieutenant Antonio Gracias. We end by discussing the risks of elite control over drugs that have been developed to shift identity — especially when those elites are simultaneously devoted to killing the so-called "woke mind virus" and remaking the global order in Palantir's image.

Foot Notes:

Executive Order (White House): https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access (Psychedelic Alpha): https://psychedelicalpha.com/news/president-trump-signs-executive-order-to-accelerate-psychedelic-research-and-access/

Over-the-top psychedelic promos could undermine the field’s drug development efforts (STAT): https://www.statnews.com/2026/03/31/psychedelic-biotech-promotion-scrutinized-helus-atai-influencer-marketing/

Archived: https://archive.is/bv1oU

Pharma lobbyists focus on a surprising new target: the FDA (STAT): https://www.statnews.com/2026/02/23/fda-lobbying-efforts-grow-under-trump-administration/ Archived: https://archive.is/wQav7

Wohin treibt die Renaissance von LSD & Co.? (WOZ)

https://www.woz.ch/2609/psychedelika/wohin-treibt-die-renaissance-von-lsd-co/!NBCC4R4K3E06

TOPICS